PHOST’IN THERAPEUTICS RAISES €10.3M TO DEVELOP FIRST-IN-CLASS NGLYCOSYLATION INHIBITORS FOR CANCER TREATMENT
Montpellier, France - April 2020, 20th
Phost’in Therapeutics (Montpellier, France), a biopharmaceutical company focused on thediscovery and development of N-glycosylation inhibitors, today announced that it has successfully
secured a €10.3 million Series A round, from an international syndicate of Life Science andInnovation Investors led by Remiges Ventures and completed by ANRI and Irdi Soridec Gestion.
The Series A funding will be used to advance the clinical development of Phost’in’s main program,
PhOx430, and to enhance capacity of its discovery platform.
A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops
a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation
mechanism responsible for suppressing the immune response.
“The aberrant glycosylation of tumor cells has been described for decades as implicated in cancer
aggressiveness and associated with poor prognostic. It is now fully recognized as a novel immune
checkpoint, masking tumor cells from the immune system via the formation of complex abnormal
glycan patterns operating as a shield,” explained Dr. Ludovic Clarion, CSO of Phost’in. “Our glycocalyx
modifiers target the aberrant glycosylation directly to the source through the selective inhibition of a
specific glycosylation enzyme, thus inducing simultaneously an anti-cancer immune response and thedown regulation of the main receptors implicated in cancer proliferation and invasiveness.”
A strong antitumoral efficacy of the first candidate PhOx430 has been demonstrated in animalmodels, associated with an excellent safety profile, which is not a surprise for experts in the field:“Regarding the weak expression and activity of the targeted enzyme in physiological state, few
adverse effects are expected. Only tumor cells are dependent on such an enzymatic activity”
summarizes Dr. Clarion.
“The 5 past years have been dedicated to qualify our main program, to optimize PhOx430 galenic
form for oral administration and to advance preclinical regulatory development. A PreIND meetingwith the FDA validated these steps a few months ago. The current Series A now provides us theresources to bring PhOx430 into clinical trials by 12 months as a single agent, with a focus onaggressive solid tumors, such as Glioblastomas and Triple Negative Breast Cancers.” adds Karine
Chorro, CEO of the company. “In parallel, it will also allow us to deepen our R&D programs, including
combinations with current available treatments to enlarge the scope of indications.”
Taro Inaba, Founder and Managing Partner of Remiges Ventures, said, "We are very excited to lead
the Phost’in Therapeutics’ Series A round of financing that provides sufficient funds to bring its
innovative lead product to the clinic. We believe that Phost’in Therapeutics’ first-in-class glycocalyx
modifiers have the potential to enhance the efficacy of immunotherapies and address the high unmet
medical need existent in the oncology and other disease areas”.
In conjunction with the Series A financing, Remiges invited Richard J. Meadows to join the board of
directors of the firm. Richard Meadows was Co-Founder of and Managing Partner at CTI Life Sciences
Fund and Partner at the Biotechnology Group of CDP Capital Technology Ventures. Hitoshi Ono from
Remiges Ventures joined the board of directors of the firm as well. Moving forward, Remiges
anticipates supporting the firm's value creation.

About Phost’in Therapeutics
Phost’in Therapeutics is a biotechnology company specialized in the discovery and development of
NCE’s specifically targeting abnormal pathogenic glycosylation mechanisms. Phost’in’s creation is theconcretization of ten years of academic works, led by a consortium of academic researchers inMontpellier and Paris. In addition to its own patents, Phost’in disposes of an exclusive licence for twofamilies of academic patents owned by CNRS (Centre National de la Recherche Scientifique), ENSCM(Ecole Nationale Supérieure de Chimie de Montpellier), and the Universities of Montpellier,Sorbonne Paris Nord and Paris Saclay. The company also leads upstream research programs inseveral other diseases using its unique expertise and discovery platform. Founded in Dec. 2014 andbased in Montpellier, France, the company was awarded a national Special Prize in the 2014 ILabcompetition of the French Research Ministry, and is supported by bpifrance, LifeScience cluster
Eurobiomed, Satt AxLR, Region Occitanie and Montpellier FranceHealthHub. www.phostin.com
About Remiges Ventures
Based in Seattle and Tokyo, Remiges Ventures is a US-Japan cross-border venture capital firm
focused on therapeutics. Remiges Ventures takes a lead position for the syndication of Series A or
later stage of investment rounds globally and actively creates new companies based on innovative
assets discovered at Japanese academic institutions. Remiges Ventures’ team is connected with serial
entrepreneurs, KOLs in various therapeutic areas, key consultants and major large pharmaceuticalcompanies in the globe. The team actively participates in the value creation for its portfolio
companies. www.remigesventures.com
About ANRIANRI is a leading seed/early stage-focused investment firm based in Tokyo, Japan. ANRI is committed
to helping exceptional founders build their next major companies. The firm invests in a wide range of
disruptive ideas and technologies from consumer service to biotechnology. Founded in 2012, ANRI
has funded more than 100 companies including Raksul, UUUM, Mirrativ, hey and more. www.anri.vc
About Irdi Soridec Gestion
Based in Toulouse, Montpellier and Bordeaux, Irdi Soridec Gestion has been supporting SMEs andmid-caps in the great south-west of France for more than 30 years in equity capital at all stages ofdevelopment (seed, creation, development and transmission). Supported by the National Seed Fund(FNA), its fund IRDInov2 is mainly focused on innovative spin-off from public or private researchorganizations. www.irdisoridec.fr
Eleom Avocats (Montpellier, France – www.eleom-avocats.com), led by partners Pascal Roze andJean-Marie Aussedat on corporate aspects, advised Phost’in Therapeutics on this fundinground. Remiges Ventures Inc. was advised by Gide (Paris, France – www.gide.com), led by counsel
Louis Oudot de Dainville, with associate Marc Fournier.

Contact:Karine Chorro, CEOcontact@phostin.com
Phost’in Therapeutics, 104 rue de la Galera, 34 090 Montpellier FRANCE